Skip to the main content.

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

Tom French : 28 July 2025

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

This article traces the evolution of API-in-capsule (AIC) technology, from its early disruption of traditional formulation through the Xcelodose® system, to its reinvention in 3P innovation’s Fill2Weight platform. The authors explore how AIC has shifted from a risky bet to a scalable solution for modern drug development. Looking ahead, they highlight the transformative role AIC can play in personalised medicine, oncology, and DPI, where flexibility and precision are key to success.

Authors:

  • Tom French (Head of Process Technology- 3P innovation)
  • Dave Miller (CSO- AustinPx)
  • Derek Hennecke (CEO- Grand River Aseptic Manufacturing)

READ THE WHITEPAPER HERE
Inside 3P innovation’s Latest DPI Blister Filling and Sealing Platform

Inside 3P innovation’s Latest DPI Blister Filling and Sealing Platform

Carl Jones: 12 August 2025

In this interview, Carl Jones, Projects Director at 3P innovation, discusses the company’s latest advancements in blister filling and sealing...

Read More
From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

Tom French: 28 July 2025

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future This article traces the evolution of API-in-capsule (AIC)...

Read More
What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

Charles Pilato: 8 August 2025

The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...

Read More